Advanced NSCLC: Adding antiangiogenic drug to second-line therapy boosts survival outcomesApril 25, 2022Lung Cancer
Advanced nonsquamous NSCLC: First-line ICI-chemo tops bevacizumab-chemo in OSApril 25, 2022Lung Cancer
Unresectable stage III NSCLC: Platinum-doublet chemotherapy beneficial as second-line therapyApril 25, 2022Lung Cancer
Stage I NSCLC: No real-world survival benefit with tegafur-uracil chemotherapyApril 25, 2022Lung Cancer
Advanced refractory ROS1+ NSCLC: Lorlatinib is safe and effective in real-world settingApril 25, 2022Lung Cancer
Oncology PracticePreop nivolumab plus chemo ‘a quantum leap’ in NSCLC therapyApril 22, 2022Lung Cancer
Oncology PracticeInternational group identifies actions to improve lung cancer survivalApril 21, 2022Lung Cancer
Oncology PracticeBetter survival in older cancer patients who take metforminApril 14, 2022Genitourinary CancerGastrointestinal CancerBreast CancerLung Cancer
